drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (biologic, cellular gene therapy; allogeneic CAR-T)
drug_description
Universal (allogeneic) anti-GCC CAR-T cell therapy made from healthy-donor T cells; engineered with a CAR whose scFv binds guanylyl cyclase C (GCC) to induce T-cell cytotoxicity and cytokine release against GCC-positive metastatic colorectal cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells engineered to express a CAR with an scFv specific for guanylyl cyclase C (GCC). Upon binding GCC on tumor cells, CAR signaling activates the T cells to release cytotoxic granules (perforin/granzymes) and cytokines, leading to targeted lysis of GCC-positive metastatic colorectal cancer cells.
drug_name
REVO-UWD-01
nct_id_drug_ref
NCT06653010